Loading…

Serum immunoglobulin G of neuro-Behçet's Disease patients reduce cerebral expression levels of survival pathway factors

Objective: Anti-neuronal antibodies are found in sera of neuro-Behçet's disease (NBD) patients. In this study, our aim was to analyze the potential mechanisms by which NBD immunoglobulin (Ig) Gs affect neuronal dysfunction. Materials and Methods: Purified IgGs obtained from pooled sera of six e...

Full description

Saved in:
Bibliographic Details
Published in:Neurological sciences and neurophysiology 2020-07, Vol.37 (3), p.118-123
Main Authors: Erdag, Ece, Şahin-Özkartal, Ceren, Küçükali, Cem, Arıcıoğlu, Feyza, Tüzün, Erdem
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c357l-babbdb868cd43691b841050eb813508cc73bc38ff72b1aed91f403616c7445d63
container_end_page 123
container_issue 3
container_start_page 118
container_title Neurological sciences and neurophysiology
container_volume 37
creator Erdag, Ece
Şahin-Özkartal, Ceren
Küçükali, Cem
Arıcıoğlu, Feyza
Tüzün, Erdem
description Objective: Anti-neuronal antibodies are found in sera of neuro-Behçet's disease (NBD) patients. In this study, our aim was to analyze the potential mechanisms by which NBD immunoglobulin (Ig) Gs affect neuronal dysfunction. Materials and Methods: Purified IgGs obtained from pooled sera of six each NBD patients and healthy controls (HCs) were administered to Sprague Dawley rats through intraventricular injection. Control rats received phosphate-buffered saline (PBS) only. Locomotor activity was assessed by open field test on days 0, 10, and 25. Cerebral expression levels of intracellular pathway factors associated with cell survival and viability were measured by real-time polymerase chain reaction. Results: Rats treated with NBD IgG exhibited reduced motor activity. On day 25, the mean number of crossings was 44 ± 7, 90 ± 12, and 93 ± 5 and the mean number of rearings was 18 ± 7, 34 ± 5, and 35 ± 6 for NBD IgG, HC IgG, and PBS groups, respectively (P < 0.001). Relative expression levels of Akt-1 (0.4 ± 0.2, 1.0 ± 0.3, and 0.9 ± 0.6; P = 0.004), DJ-1 (0.6 ± 0.2, 1.0 ± 0.6, and 0.9 ± 0.5; P = 0.047), mouse double mininute-2 (0.5 ± 0.3, 0.9 ± 0.2, and 1.0 ± 0.2; P = 0.002), and mechanistic target of rapamycin (0.4 ± 0.2, 0.8 ± 0.4, and 0.9 ± 0.6; P = 0.006) were significantly lower in NBD-IgG group than HC IgG and PBS groups. By contrast, the expression levels of factors associated with apoptosis (caspase 3, mitochondrial carrier homolog 1, and B-cell lymphoma-2) were comparable among different treatment arms. Conclusion: Our results suggest that at least a fraction of NBD IgG interacts with neuronal surface antigens and subsequently decreases neuronal viability through Akt pathway inhibition. By contrast, NBD IgG does not appear to activate neuronal apoptosis. Further identification of the binding sites of serum IgG ıs required.
doi_str_mv 10.4103/NSN.NSN_2_20
format article
fullrecord <record><control><sourceid>wolterskluwer_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_6ea8f20255e14240b546c2307ea3bb19</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_6ea8f20255e14240b546c2307ea3bb19</doaj_id><sourcerecordid>10.4103/NSN.NSN_2_20_118_Serum immunogl</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357l-babbdb868cd43691b841050eb813508cc73bc38ff72b1aed91f403616c7445d63</originalsourceid><addsrcrecordid>eNptkUtOwzAQQCMEEgjYcQDv2BDwJ3bcJX8qVbAAJHaW7UzA4MSVnbRwIg7CxUhbiliwGM1oPk8avSw7IPi4IJid3N7fHg-hqKJ4I9uhgolcCv60-afezvZTesUYU8xGQvCd7P0eYt8g1zR9G559ML13LbpGoUYt9DHkZ_Dy9QndYUIXLoFOgKa6c9B2CUWoegvIQgQTtUfwPo2Qkgst8jADnxaU1MeZmw3T4exlrj9QrW0XYtrLtmrtE-z_5N3s8ery4fwmn9xdj89PJ7llvPS50cZURgppq4KJETFyeJZjMJIwjqW1JTOWybouqSEaqhGpC8wEEbYsCl4JtpuNV9wq6Fc1ja7R8UMF7dSyEeKz0rFz1oMSoGVNMeUcSEELbHghLGW4BM2MIaOBdbRi2RhSilD_8ghWCwlqIWAtYVi_WK3Pg-8gpjffzyGqBqq3Nsz_vVGESLVUotZK2DeTmpWi</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Serum immunoglobulin G of neuro-Behçet's Disease patients reduce cerebral expression levels of survival pathway factors</title><source>DOAJ Directory of Open Access Journals</source><creator>Erdag, Ece ; Şahin-Özkartal, Ceren ; Küçükali, Cem ; Arıcıoğlu, Feyza ; Tüzün, Erdem</creator><creatorcontrib>Erdag, Ece ; Şahin-Özkartal, Ceren ; Küçükali, Cem ; Arıcıoğlu, Feyza ; Tüzün, Erdem</creatorcontrib><description>Objective: Anti-neuronal antibodies are found in sera of neuro-Behçet's disease (NBD) patients. In this study, our aim was to analyze the potential mechanisms by which NBD immunoglobulin (Ig) Gs affect neuronal dysfunction. Materials and Methods: Purified IgGs obtained from pooled sera of six each NBD patients and healthy controls (HCs) were administered to Sprague Dawley rats through intraventricular injection. Control rats received phosphate-buffered saline (PBS) only. Locomotor activity was assessed by open field test on days 0, 10, and 25. Cerebral expression levels of intracellular pathway factors associated with cell survival and viability were measured by real-time polymerase chain reaction. Results: Rats treated with NBD IgG exhibited reduced motor activity. On day 25, the mean number of crossings was 44 ± 7, 90 ± 12, and 93 ± 5 and the mean number of rearings was 18 ± 7, 34 ± 5, and 35 ± 6 for NBD IgG, HC IgG, and PBS groups, respectively (P &lt; 0.001). Relative expression levels of Akt-1 (0.4 ± 0.2, 1.0 ± 0.3, and 0.9 ± 0.6; P = 0.004), DJ-1 (0.6 ± 0.2, 1.0 ± 0.6, and 0.9 ± 0.5; P = 0.047), mouse double mininute-2 (0.5 ± 0.3, 0.9 ± 0.2, and 1.0 ± 0.2; P = 0.002), and mechanistic target of rapamycin (0.4 ± 0.2, 0.8 ± 0.4, and 0.9 ± 0.6; P = 0.006) were significantly lower in NBD-IgG group than HC IgG and PBS groups. By contrast, the expression levels of factors associated with apoptosis (caspase 3, mitochondrial carrier homolog 1, and B-cell lymphoma-2) were comparable among different treatment arms. Conclusion: Our results suggest that at least a fraction of NBD IgG interacts with neuronal surface antigens and subsequently decreases neuronal viability through Akt pathway inhibition. By contrast, NBD IgG does not appear to activate neuronal apoptosis. Further identification of the binding sites of serum IgG ıs required.</description><identifier>ISSN: 2636-865X</identifier><identifier>EISSN: 2636-865X</identifier><identifier>DOI: 10.4103/NSN.NSN_2_20</identifier><language>eng</language><publisher>Wolters Kluwer India Pvt. Ltd</publisher><subject>akt pathway ; behçet's disease ; immunoglobulin g ; inflammation ; neuro-behçet's disease</subject><ispartof>Neurological sciences and neurophysiology, 2020-07, Vol.37 (3), p.118-123</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c357l-babbdb868cd43691b841050eb813508cc73bc38ff72b1aed91f403616c7445d63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,2102,27924,27925</link.rule.ids></links><search><creatorcontrib>Erdag, Ece</creatorcontrib><creatorcontrib>Şahin-Özkartal, Ceren</creatorcontrib><creatorcontrib>Küçükali, Cem</creatorcontrib><creatorcontrib>Arıcıoğlu, Feyza</creatorcontrib><creatorcontrib>Tüzün, Erdem</creatorcontrib><title>Serum immunoglobulin G of neuro-Behçet's Disease patients reduce cerebral expression levels of survival pathway factors</title><title>Neurological sciences and neurophysiology</title><description>Objective: Anti-neuronal antibodies are found in sera of neuro-Behçet's disease (NBD) patients. In this study, our aim was to analyze the potential mechanisms by which NBD immunoglobulin (Ig) Gs affect neuronal dysfunction. Materials and Methods: Purified IgGs obtained from pooled sera of six each NBD patients and healthy controls (HCs) were administered to Sprague Dawley rats through intraventricular injection. Control rats received phosphate-buffered saline (PBS) only. Locomotor activity was assessed by open field test on days 0, 10, and 25. Cerebral expression levels of intracellular pathway factors associated with cell survival and viability were measured by real-time polymerase chain reaction. Results: Rats treated with NBD IgG exhibited reduced motor activity. On day 25, the mean number of crossings was 44 ± 7, 90 ± 12, and 93 ± 5 and the mean number of rearings was 18 ± 7, 34 ± 5, and 35 ± 6 for NBD IgG, HC IgG, and PBS groups, respectively (P &lt; 0.001). Relative expression levels of Akt-1 (0.4 ± 0.2, 1.0 ± 0.3, and 0.9 ± 0.6; P = 0.004), DJ-1 (0.6 ± 0.2, 1.0 ± 0.6, and 0.9 ± 0.5; P = 0.047), mouse double mininute-2 (0.5 ± 0.3, 0.9 ± 0.2, and 1.0 ± 0.2; P = 0.002), and mechanistic target of rapamycin (0.4 ± 0.2, 0.8 ± 0.4, and 0.9 ± 0.6; P = 0.006) were significantly lower in NBD-IgG group than HC IgG and PBS groups. By contrast, the expression levels of factors associated with apoptosis (caspase 3, mitochondrial carrier homolog 1, and B-cell lymphoma-2) were comparable among different treatment arms. Conclusion: Our results suggest that at least a fraction of NBD IgG interacts with neuronal surface antigens and subsequently decreases neuronal viability through Akt pathway inhibition. By contrast, NBD IgG does not appear to activate neuronal apoptosis. Further identification of the binding sites of serum IgG ıs required.</description><subject>akt pathway</subject><subject>behçet's disease</subject><subject>immunoglobulin g</subject><subject>inflammation</subject><subject>neuro-behçet's disease</subject><issn>2636-865X</issn><issn>2636-865X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNptkUtOwzAQQCMEEgjYcQDv2BDwJ3bcJX8qVbAAJHaW7UzA4MSVnbRwIg7CxUhbiliwGM1oPk8avSw7IPi4IJid3N7fHg-hqKJ4I9uhgolcCv60-afezvZTesUYU8xGQvCd7P0eYt8g1zR9G559ML13LbpGoUYt9DHkZ_Dy9QndYUIXLoFOgKa6c9B2CUWoegvIQgQTtUfwPo2Qkgst8jADnxaU1MeZmw3T4exlrj9QrW0XYtrLtmrtE-z_5N3s8ery4fwmn9xdj89PJ7llvPS50cZURgppq4KJETFyeJZjMJIwjqW1JTOWybouqSEaqhGpC8wEEbYsCl4JtpuNV9wq6Fc1ja7R8UMF7dSyEeKz0rFz1oMSoGVNMeUcSEELbHghLGW4BM2MIaOBdbRi2RhSilD_8ghWCwlqIWAtYVi_WK3Pg-8gpjffzyGqBqq3Nsz_vVGESLVUotZK2DeTmpWi</recordid><startdate>20200701</startdate><enddate>20200701</enddate><creator>Erdag, Ece</creator><creator>Şahin-Özkartal, Ceren</creator><creator>Küçükali, Cem</creator><creator>Arıcıoğlu, Feyza</creator><creator>Tüzün, Erdem</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Wolters Kluwer Medknow Publications</general><scope>AAYXX</scope><scope>CITATION</scope><scope>DOA</scope></search><sort><creationdate>20200701</creationdate><title>Serum immunoglobulin G of neuro-Behçet's Disease patients reduce cerebral expression levels of survival pathway factors</title><author>Erdag, Ece ; Şahin-Özkartal, Ceren ; Küçükali, Cem ; Arıcıoğlu, Feyza ; Tüzün, Erdem</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357l-babbdb868cd43691b841050eb813508cc73bc38ff72b1aed91f403616c7445d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>akt pathway</topic><topic>behçet's disease</topic><topic>immunoglobulin g</topic><topic>inflammation</topic><topic>neuro-behçet's disease</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Erdag, Ece</creatorcontrib><creatorcontrib>Şahin-Özkartal, Ceren</creatorcontrib><creatorcontrib>Küçükali, Cem</creatorcontrib><creatorcontrib>Arıcıoğlu, Feyza</creatorcontrib><creatorcontrib>Tüzün, Erdem</creatorcontrib><collection>CrossRef</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Neurological sciences and neurophysiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Erdag, Ece</au><au>Şahin-Özkartal, Ceren</au><au>Küçükali, Cem</au><au>Arıcıoğlu, Feyza</au><au>Tüzün, Erdem</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum immunoglobulin G of neuro-Behçet's Disease patients reduce cerebral expression levels of survival pathway factors</atitle><jtitle>Neurological sciences and neurophysiology</jtitle><date>2020-07-01</date><risdate>2020</risdate><volume>37</volume><issue>3</issue><spage>118</spage><epage>123</epage><pages>118-123</pages><issn>2636-865X</issn><eissn>2636-865X</eissn><abstract>Objective: Anti-neuronal antibodies are found in sera of neuro-Behçet's disease (NBD) patients. In this study, our aim was to analyze the potential mechanisms by which NBD immunoglobulin (Ig) Gs affect neuronal dysfunction. Materials and Methods: Purified IgGs obtained from pooled sera of six each NBD patients and healthy controls (HCs) were administered to Sprague Dawley rats through intraventricular injection. Control rats received phosphate-buffered saline (PBS) only. Locomotor activity was assessed by open field test on days 0, 10, and 25. Cerebral expression levels of intracellular pathway factors associated with cell survival and viability were measured by real-time polymerase chain reaction. Results: Rats treated with NBD IgG exhibited reduced motor activity. On day 25, the mean number of crossings was 44 ± 7, 90 ± 12, and 93 ± 5 and the mean number of rearings was 18 ± 7, 34 ± 5, and 35 ± 6 for NBD IgG, HC IgG, and PBS groups, respectively (P &lt; 0.001). Relative expression levels of Akt-1 (0.4 ± 0.2, 1.0 ± 0.3, and 0.9 ± 0.6; P = 0.004), DJ-1 (0.6 ± 0.2, 1.0 ± 0.6, and 0.9 ± 0.5; P = 0.047), mouse double mininute-2 (0.5 ± 0.3, 0.9 ± 0.2, and 1.0 ± 0.2; P = 0.002), and mechanistic target of rapamycin (0.4 ± 0.2, 0.8 ± 0.4, and 0.9 ± 0.6; P = 0.006) were significantly lower in NBD-IgG group than HC IgG and PBS groups. By contrast, the expression levels of factors associated with apoptosis (caspase 3, mitochondrial carrier homolog 1, and B-cell lymphoma-2) were comparable among different treatment arms. Conclusion: Our results suggest that at least a fraction of NBD IgG interacts with neuronal surface antigens and subsequently decreases neuronal viability through Akt pathway inhibition. By contrast, NBD IgG does not appear to activate neuronal apoptosis. Further identification of the binding sites of serum IgG ıs required.</abstract><pub>Wolters Kluwer India Pvt. Ltd</pub><doi>10.4103/NSN.NSN_2_20</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2636-865X
ispartof Neurological sciences and neurophysiology, 2020-07, Vol.37 (3), p.118-123
issn 2636-865X
2636-865X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_6ea8f20255e14240b546c2307ea3bb19
source DOAJ Directory of Open Access Journals
subjects akt pathway
behçet's disease
immunoglobulin g
inflammation
neuro-behçet's disease
title Serum immunoglobulin G of neuro-Behçet's Disease patients reduce cerebral expression levels of survival pathway factors
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T16%3A14%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wolterskluwer_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20immunoglobulin%20G%20of%20neuro-Beh%C3%A7et's%20Disease%20patients%20reduce%20cerebral%20expression%20levels%20of%20survival%20pathway%20factors&rft.jtitle=Neurological%20sciences%20and%20neurophysiology&rft.au=Erdag,%20Ece&rft.date=2020-07-01&rft.volume=37&rft.issue=3&rft.spage=118&rft.epage=123&rft.pages=118-123&rft.issn=2636-865X&rft.eissn=2636-865X&rft_id=info:doi/10.4103/NSN.NSN_2_20&rft_dat=%3Cwolterskluwer_doaj_%3E10.4103/NSN.NSN_2_20_118_Serum%20immunogl%3C/wolterskluwer_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c357l-babbdb868cd43691b841050eb813508cc73bc38ff72b1aed91f403616c7445d63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true